This is both biological rational and pragmatic, rational because this approach targets the 2 main pathologies of AD and simultaneously addressing both is expected to have more benefit across a broad range of disease stages (Fig. 1), and pragmatic because Aβ immunotherapy is likely to become standard of care in certain geographies such that the testing of tau targeting agents may need to be done as add-on’s. Here, MAPT is linked to Alzheimer disease.